Brief: Intensity Therapeutics Provides Update on Progress In Phase 3 Sarcoma Program
03/01/2024 13:09
Jan 3 (Reuters) - Intensity Therapeutics Inc INTS.O :
* INTENSITY THERAPEUTICS PROVIDES BUSINESS UPDATE REFLECTING
PROGRESS IN PHASE 3 SARCOMA PROGRAM
* FDA PROVIDES "STUDY MAY PROCEED" LETTER FOR OPEN-LABEL,
RANDOMIZED PHASE 3 PROTOCOL IN SOFT TISSUE SARCOMA
* PLANS TO INITIATE PHASE 3 STUDY IN FIRST HALF OF 2024
Source text for Eikon: ID:nPn7RTRYXa
Further company coverage: INTS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intensity Therapeutics
See all newsIntensity Therapeutics Q2 net loss widens as R&D costs rise
Brief: Intensity Therapeutics Q2 Operating Income USD -3.084 Million
Intensity Therapeutics Q1 net loss narrows on lower R&D costs
Brief: Intensity Therapeutics Q1 Operating Income USD -2.526 Million
Brief: Intensity Therapeutics Inc - Increases ATM Offering Capacity To $60 Million On March 23, 2026 - SEC Filing